Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Multiple sclerosis may not put you at risk for breast, colorectal cancerson November 25, 2020 at 1:05 pm
People with multiple sclerosis (MS) may not be at higher risk of developing two of the three cancers that occur most commonly in people with MS, breast and colorectal cancer, than people who don't ...
- MediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosison November 25, 2020 at 8:58 am
(NASDAQ:MNOV) announces that positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) were ...
- 'Talking about it saves lives': Suicide survivor with multiple sclerosis shares her storyon November 24, 2020 at 2:37 am
Chloe Bellerby survived a suicide attempt as a teen, came from England to play soccer, and is an advocate for mental health and multiple sclerosis.
- Multiple Sclerosis Market Size Report 2020 Global Industry Analysis by Trends, Revenue, Share, Revenue and Forecast to 2025on November 23, 2020 at 2:54 am
Final Report will add the analysis of the impact of COVID-19 on this industry." “Multiple Sclerosis Market” has ...
- Gut-brain axis influences multiple sclerosison November 20, 2020 at 11:10 am
A Basel-led international research team has discovered a connection between the intestinal flora and sites of inflammation in the central nervous system in multiple sclerosis. A specific class of ...
- New research underscores the link between multiple sclerosis and the gut microbiomeon November 20, 2020 at 11:08 am
People with multiple sclerosis have elevated levels of immune cells in their brains that are associated with gut microbiota, the paper finds.
- 1 year after multiple sclerosis diagnosis, WTOP’s Dave Johnson looks back, forwardon November 19, 2020 at 2:06 am
One year after revealing he had been diagnosed with multiple sclerosis, WTOP’s Dave Johnson provides an update on his condition and outlook.
- Leading Neurologist Shares Experiences of Treating Multiple Sclerosis (MS) Patients (FCL Nov. 17)on November 18, 2020 at 5:07 pm
According to an estimate from the National Multiple Sclerosis Society, nearly 1 million people over the age of 18 are living with MS in the United States. MS is a chronic and unpredictable disease of ...
- The Challenges of Relapsing Multiple Sclerosis (MS) Can Add Upon November 18, 2020 at 4:23 am
From experiencing relapses, to worrying about what may come next and managing the demands of life around treatment schedules—the challenges of living with MS can really add up. When they do, it may be ...
via Bing News